# Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies

> **NCT00979563** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 15 (actual)

## Conditions studied

- Advanced Solid Malignancies

## Interventions

- **DRUG:** HM30181AK tablet + Irinotecan tablets

## Key facts

- **NCT ID:** NCT00979563
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2010-03
- **Final completion:** 2010-11
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2011-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00979563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00979563, "Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00979563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*